Trials / Completed
CompletedNCT02562807
A Study of TAS-303 in Female Patients With Stress Urinary Incontinence
A Phase I Study of TAS-303 in Female Patients With Stress Urinary Incontinence
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Taiho Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate pharmacological effect, safety and pharmacokinetic of TAS-303 in female patients with Stress Urinary Incontinence.
Detailed description
This study is double-blind, placebo-controlled crossover study. The main purpose of this study is to evaluate Urethral Pressure Profile Parameters in Stress Urinary Incontinence patients who will receive single dose of TAS-303 or Placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS-303 18mg single-dose | |
| DRUG | Placebo 18mg single-dose | |
| DRUG | TAS-303 9mg single-dose | |
| DRUG | Placebo 9mg single-dose |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2015-12-01
- Completion
- 2016-03-01
- First posted
- 2015-09-29
- Last updated
- 2016-08-10
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02562807. Inclusion in this directory is not an endorsement.